Aniline → HCID 59593039, compound

HRID 2098727Notes

Reaction equation

HRID 2098727 reaction equation
[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[S:18][C:17]([C:19]([OH:21])=O)=[CH:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1.[NH2:28][C:29]1[CH:34]=[CH:33][CH:32]=[CH:31][CH:30]=1>>[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:23][CH2:24][O:25][CH2:26][CH2:27]4)[C:13]4[S:18][C:17]([C:19]([NH:28][C:29]5[CH:34]=[CH:33][CH:32]=[CH:31][CH:30]=5)=[O:21])=[CH:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1

Participants

3

Reactant 2

HCID 6115AnilineHCID 595931412-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid

Product 1

HCID 59593039HCID 59593039, compound

Procedure

2-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid 13 (30 mg) was coupled to aniline via General Procedure B. The product was purified via reverse phase HPLC to give 6.4 mg of 247. MS (Q1) 456.8 (M)+.

Workup

  1. customThe product was purified via reverse phase HPLC

Sources & evidence

ORD record
ord-9f22cb46094e4062973f0115ea62e97c
Source dataset
uspto-grants-2013_05
Patent number
US08450315B2

Reaction notes

Loading…